When multiple myeloma relapses
RESPOND with a treatment studied in 860 patients with relapsed multiple myeloma*
ASPIRE: a pivotal phase 3 study1
Adapted from Stewart et al.1
Survival rates have improved for multiple myeloma patients but relapse is still an issue, so there remains a need for new treatment approaches.1
Kyprolis® has been studied in combination with standard of care regimens to determine how it improves key efficacy endpoints.
Design:
The ASPIRE study was a randomised, open-label, multicentre, phase 3 study.1
Aim:
To evaluate the safety and efficacy of Kyprolis® with lenalidomide and weekly dexamethasone vs lenalidomide and weekly dexamethasone alone in patients with relapsed multiple myeloma. 1
Population:
792 patients with relapsed multiple myeloma who had received 1–3 previous therapeutic regimens.1
Primary endpoint:
Progression-free survival.1
Secondary endpoints:
Included overall survival, the rate of overall response (partial response or better), duration of response, health-related quality of life, and safety.1
See the detailed treatment regimens in the ASPIRE study See the efficacy results from the ASPIRE study
*396 patients received KRd in the pivotal phase 3 ASPIRE study1 and 464 patients received Kd in the head-to-head phase 3 ENDEAVOR study2
Please read the SmPC for full comprehensive safety information
References
- Stewart AK et al. N Engl J Med 2015;372:142–152.
- Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.
When multiple myeloma relapses
Treatment regimens in ASPIRE (KRd vs Rd)
KRd regimen
- Kyprolis: cycles 1−12: 27 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 (20 mg/m2 IV on days 1 and 2 of cycle 1 only); cycles 13−18*: 27 mg/m2 IV on days 1, 2, 15 and 16
- Lenalidomide: 25 mg on days 1−21
- Dexamethasone: 40 mg on days 1, 8, 15 and 22
Rd Regimen
- Lenalidomide: 25 mg on days 1−21
- Dexamethasone: 40 mg on days 1, 8, 15 and 22
Prior treatments
- Number of prior treatments: median: 2, range: 1–3
- Bortezomib: 66%
- Lenalidomide: 20%
*Kyprolis® was discontinued after 18 cycles
